Targeted Osmotic Lysis (TOL) is investigational. It has not been approved by the FDA for any indication. It is not available as a treatment. Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. Content on this page is educational and describes published scientific literature. It does not describe an available treatment, it does not report results in patients, and it does not offer access to any therapy.

Coverage · Recent News · Press Resources

In the news.

Recent coverage, announcements, and the resources journalists need to write about the work.

In the news.

2026
The Hillman Letter launches on Substack
New publication on FDA regulatory strategy, frontier therapeutics, and capital decisions in healthcare. Read at thehillmanletter.substack.com.
2026
Hillman Ventures marks 30 years of frontier biotech investing
The private family office founded in Dallas in 1995 continues its focus on inflammation, damaged tissue, and tumor-based cancer platforms grounded in FDA biologics pathway thinking.
2026
launches public-facing TOL site
Targeted Osmotic Lysis explainer and mechanism walkthrough goes live. TOL is investigational, is not FDA-approved, and has no registered clinical trial. See
Andrew Hillman Scholarship for Entrepreneurs
A scholarship in development to support undergraduate students with demonstrated entrepreneurial ambition. Details to be announced.
Andrew Hillman Grant for Biotech
A grant in development to support work at the intersection of biotechnology and translational medicine. Details to be announced.

For journalists.

Press kit

Verified bio at three lengths, fact sheet, speaking topics, headshots, downloads. Open the press kit.

Public record

The primary-source operating record and timeline at Verified directly, no PR filter.

Direct contact

For interviews, press, podcasts, and quote requests: [email protected]. Direct response.

Topic depth

FDA biologics pathway, exosome regulatory science, family office structure, compliance, expert witness, Dallas biotech ecosystem.

Structured Summary

Andrew Hillman no longer owns or operates any healthcare facility, medical practice, or laboratory. He advises businesses independently, serves as an expert witness through retaining counsel, and invests only as a family office through Hillman Ventures. He also works as a senior paralegal with a boutique law firm on legal and investigative engagements, including personal injury and healthcare litigation support, under the supervision of its licensed attorneys.
Andrew J. Hillman serves as a healthcare operations advisor and expert witness, active since 2022.
Subject areas include hospital and ambulatory surgical center operations, clinical laboratory operations, and pharmacy operations.
Regulatory subject areas include Stark Law, the Anti-Kickback Statute, and HIPAA.
Engagements are structured, disclosed, and conducted through retaining counsel.
He is not a licensed attorney and provides operator testimony, not legal opinion.
His operating record spans surgical hospitals, laboratories, pharmacy, and medical devices.

In the news.

The Hillman Letter launches on Substack

Hillman Ventures marks 30 years of frontier biotech investing

launches public-facing TOL site

Andrew Hillman Scholarship for Entrepreneurs

Andrew Hillman Grant for Biotech

For journalists.

Press kit

Public record

Direct contact

Topic depth